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Abstract
Background: Brucellosis is a persistent health problem in many developing countries throughout the world, and the search
for simple and effective treatment continues to be of great importance.
Methods and Findings: A search was conducted in MEDLINE and in the Cochrane Central Register of Controlled Trials
(CENTRAL). Clinical trials published from 1985 to present that assess different antimicrobial regimens in cases of
documented acute uncomplicated human brucellosis were included. The primary outcomes were relapse, therapeutic
failure, combined variable of relapse and therapeutic failure, and adverse effect rates. A meta-analysis with a fixed effect
model was performed and odds ratio with 95% confidence intervals were calculated. A random effect model was used when
significant heterogeneity between studies was verified. Comparison of combined doxycycline and rifampicin with a
combination of doxycycline and streptomycin favors the latter regimen (OR=3.17; CI95%=2.05–4.91). There were no
significant differences between combined doxycycline-streptomycin and combined doxycycline-gentamicin (OR=1.89;
CI95%=0.81–4.39). Treatment with rifampicin and quinolones was similar to combined doxycycline-rifampicin (OR=1.23;
CI95%=0.63–2.40). Only one study assessed triple therapy with aminoglycoside-doxycycline-rifampicin and only included
patients with uncomplicated brucellosis. Thus this approach cannot be considered the therapy of choice until further
studies have been performed. Combined doxycycline/co-trimoxazole or doxycycline monotherapy could represent a cost-
effective alternative in certain patient groups, and further studies are needed in the future.
Conclusions: Although the preferred treatment in uncomplicated human brucellosis is doxycycline-aminoglycoside
combination, other treatments based on oral regimens or monotherapy should not be rejected until they are better studied.
Triple therapy should not be considered the current treatment of choice.
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Introduction
Brucellosis is one of the most common zoonotic diseases world-
wide [1] and it continues to be a health problem in developing
countries. Despite the existence of effective treatments, it may be
responsible for high morbidity [2,3]. The most common
treatments are combined doxycycline and rifampicin for 6 weeks
[4], and doxycycline for 6 weeks combined with an aminoglyco-
side (primarily streptomycin or gentamicin) [5] over the first few
days of treatment. However, there are still a number of obstacles to
overcome, such as the need for parenteral administration of
aminoglycosides, the danger of inducing rifampicin resistance in
countries where tuberculosis poses a problem, treatment compli-
ance in a disease in which symptoms disappear a few days after
initiating treatment, the difficulty of patient follow-up in
underdeveloped rural areas, and the relapses, which affect
approximately 10% of the patients [5,6]. Furthermore, ever since
the first effective treatments against brucellosis appeared (based on
combined sulphonamides or tetracyclines and aminoglycosides),
antimicrobial combinations have been preferred over monother-
apy, and alternative that has seldom been used and studied. On
the other hand, brucellosis may be complicated by endocarditis,
neurobrucellosis or osteoarticular infections such as spondylitis.
These forms may require longer or more aggressive treatment
than uncomplicated brucellosis, and they should be studied
separately.
In 1990, Hall [7] published an extensive review of treatments
for human brucellosis in which he pointed out that until then there
had been only four comparative prospective randomized studies
concerning the therapeutic options for brucellosis. Two of these
studies were published by Ariza et al. in 1985 [8,9], another by
Acocella et al. in 1989 [10] and a further study by Colmenero et al.
in 1989 [11]. In the past 25 years, the results of other clinical trials
have been published, as well as various reviews and meta-analyses
aimed at identifying the best treatment for brucellosis [12–14]. In
the most recent of these papers, published in 2008 [14], Skalsky et
al. recommended a combination of three drugs as the therapy of
choice for human brucellosis (doxycycline, rifampicin for 6 to 8
weeks, and aminoglycoside for 7 to 14 days). This recommenda-
tion is based on two studies. One study, involved the comparison
of 5 different therapeutic regimens in 102 patients with lumbar
spondylitis [15] and concluded recommending streptomycin for 15
days and doxycycline and rifampicin for 45 days in these cases.
However, in patients with focal complications of brucellosis such
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may be necessary than in patients with uncomplicated brucellosis.
The second study [16] compared amikacin for 7 days combined
with doxycycline and rifampicin for 8 to 12 weeks vs. doxycycline
and rifampicin also for a period of 8 to 12 weeks. The conclusions
of this study were based on a lower treatment failure rate (as
defined by the disappearance of fever and symptoms) associated
with the triple therapy, with limited significance (p=0.04,
CI=95%: 0.008–0.15) when compared with the doxycycline-
rifampicin regimen. Specifically, 92.2% of patients were afebrile
after two weeks of treatment with triple therapy, and 68% were
afebrile with combined doxycycline-rifampicin, in sharp contrast
to other studies [8,17–22]. The study revealed no differences in
terms of relapse (p=0.4). Triple therapy makes treatment more
complicated, increases costs and makes administration more
difficult, especially in developing countries. These results illustrate
that the need for better and inexpensive treatments remains.
Further, combining data from such different forms of brucellosis as
spondylitis and non-focal brucellosis may be inapropiate and could
lead to erroneous conclusions.
The ideal treatment should be given orally, thus increasing
compliance, and should not involve increased rates of relapse or
treatment failure. In this paper, a critical review of published data
will be presented in order to identify therapeutic regimens allowing
effective and easy-to-use treatment, and a number of questions will
be posed that must be examined in future studies. The aim is to
determine which of the standard therapeutic approaches is the
most advisable, whether there are any alternative approaches,
whether triple therapy could be recommended as the best option
in view of current data, whether monotherapy represents a valid




A search was conducted for all studies assessing different
antimicrobial regimens in the treatment of human brucellosis from
1985 until the present day. The studies included are those
comprising cases of brucellosis identified by isolation of bacteria of
the Brucella genus or by clinical and serological signs consistent
with acute Brucella spp infection.
The studies were identified by means of a MEDLINE search
using the terms ‘‘brucella’’ or ‘‘human brucellosis’’, and ‘‘treatment’’ or
‘‘therapy’’ and ‘‘clinical trial’’. This search yielded 102 studies
(January 2011), 52 of which were rejected because they were
veterinary studies (21), lied outside the timeframe of the review
(11), did not refer to brucellosis (8), were review articles (7) or were
experimental laboratory studies(5). Of the 50 remaining studies, 12
were not studies of antimicrobial therapy, 8 were non-randomized,
6 involved investigation of osteoarticular brucellosis or brucellar
endocarditis and 1 was a traditional Chinese medicine survey. The
23 remaining studies were randomized clinical trials in patients
presenting acute brucellosis. One of these was a study published by
Rodrı ´guez Zapata et al. [23], which was excluded because the
results are included in another and more extensive study [10].
Twenty two studies were thus selected. A search of the Cochrane
Central Register of Controlled Trials (CENTRAL) was conducted
for studies related to the term ‘‘brucellosis’’, which resulted in the
identification of two additional studies meeting the criteria for
inclusion in our analysis. The bibliographic references of the
selected articles were also examined in search of other possible
publications not found in the above-mentioned databases (Text S1
and table S1). Study flow diagram is shown in figure 1.
Selection criteria
Studies comparing two or more antibiotic treatment regimens in
human brucellosis were analyzed. Only studies with fully
characterized patients in terms of diagnosis, treatment adminis-
tered, and duration and dosage of treatment were selected, and
they also had to include a minimum follow-up period of six
months. The analysis included studies of patients with acute
brucellosis, and excluded studies performed solely on patients with
focal osteoarticular brucellosis, neurobrucellosis or brucellar
endocarditis. Congress abstracts were not included.
Studies without adequate details of the drugs, the doses or the
duration of treatment, were excluded. Also excluded were the
studies in which diagnostic criteria were not specified, which failed
to meet the above-set criteria (with a follow-up of less than six
months) (excluded studies are listed in table S2).
In addition, data in non-comparative studies were separately
and complementarily searched, in order to obtain information of
regimens not included in randomized comparative studies.
Although these studies are cited in the initial description of each
regimen, they were not included in the aforementioned statistical
analysis, and the non-comparative nature of the test or study is
indicated in each case.
An additional section with information collected from case
series with 100 or more patients published over the past 10 years is
also included, in which data concerning treatment and clinical
outcome as well as information concerning the use of the regimens
in the clinical practice is provided. Smaller patient series or
individual case studies were not considered.
Outcome measures
The main parameters considered in the evaluation of the
different regimens were:
N Number of relapses. Relapse was defined as the reappearance
of signs or symptoms of the disease or positive culture results
after completion of therapy during follow-up, all occurring
after an asymptomatic period.
N Therapeutic failure, defined as persistence of signs and/or
symptoms beyond a period after the beginning of treatment
considered appropriate in the various studies.
N A combined variable comprising relapse and therapeutic
failure taken together.
N Side effects of the various regimens, classified as serious when
withdrawal of the drug was required, and as moderate when
treatment withdrawal or change of therapy was not required.
N Mortality.
Another aim was to determine the time lapse between the start
of antimicrobial treatment and the disappearance of fever and
other symptoms.
Data extraction and quality assessment
Two investigators extracted independently data from studies.
Discrepancies were noted and discussed between reviewers and
resolved by consensus. For each study, the following data were
recorded:
N Year of publication
N Study type (randomization and blinding)
N Number of patients treated.
N Diagnostic criteria and exclusion criteria.
N Number of patients lost to follow-up and the reason for it.
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route of administration
N Percentage of patients with focal disease in each study
N Number of relapses and treatment failures
N Time lapse between the beginning of treatment and the
disappearance of fever or symptoms
N Follow-up period
N Side effects of medication, with indication of effects requiring
treatment withdrawal
N Mortality
N Whether patients were admitted to a hospital at the beginning
of or during treatment.
The adequate generation of allocation sequence and conceal-
ment of allocation (assessment of selection bias), blinding
(assessment of performance bias), and incomplete outcome data
(attrition bias) was determined for each study. These components
were graded as high risk, low risk or unclear risk of bias (table S3).
Data synthesis and analysis
For comparative randomized clinical trials, an analysis was
performed comparing the various therapeutic regimens in terms of
relapse, therapeutic failure, the combined variable of relapse and
therapeutic failure, mortality and side effects, wherever such
comparison was possible. The differences between the two
regimens compared in each case are expressed as an odds ratio
with the relevant confidence interval (CI95%), and were
contrasted using the Mantel-Haenszel test, using the procedure
for random effect and stratified analysis where heterogeneity
between studies was found. Where the use of these methods was
necessary, it is indicated in the text. The Rosenthal tolerance index
and a funnel plot were used to evaluate potential selection bias in
the studies. Cochran’s Q statistic and the I
2 inconsistency statistic
were used to measure heterogeneity regarding study results. In all
statistical tests, the level of statistical significance used was p,0.05.
Analyses were performed using RevMan version 5.
Results
Details of the clinical trials on the treatment of brucellosis are
given in Table S4. Table S5 shows non-randomized and non-
comparative studies designed to assess a given treatment regimen.
Description of the different regimens studied
Combinations involving parenteral drugs. A combination
of tetracyclines and streptomycin is the most widely studied of the
regimens including aminoglycosides. In a study published in 1985,
Ariza et al. [8] investigated a regimen comprising 3 weeks of
streptomycin and 30 days of oral tetracycline or doxycycline, used
indiscriminately, in 28 patients. Acocella et al. [10] investigated a
shorter regimen comprising 2 weeks of streptomycin and 21 days
of tetracycline. There is a wide discrepancy between the results of
these two studies: in the first, relapse occurred in only 7.1% of
patients compared to 22.2% in the latter, to which an 18.52%
treatment failure rate must be added, including one patient who
stopped taking the medication due to side effects.
Twelve studies investigated doxycycline and streptomycin with
similar results [10,11,17,18,20,24–30]. One of these studies was
performed in children and the study by Cisneros et al. [24] was
non-comparative. Considering the remaining 10 studies, the
regimen of doxycycline and streptomycin was investigated in
597 patients. Twenty seven patients had a relapse (4.5%; range: 0–
9.7%), and the percentage of relapse was less than 10% in any of
the studies. The combined variable of relapse and treatment
failure is 44 patients (7.4%: range: 0 and 12.5%). The study with
the highest rate of relapse and treatment failures combined was
that by Ersoy et al. published in 2005, with 12.8% [26]. One group
of 4 studies used streptomycin for 3 weeks [11,25,26,29] and a
second group of 6 studies used streptomycin for 2 weeks
[10,17,18,20,27,28]. The overall percentage of relapse and
treatment failure in the former was 6.9% (10 out of 145 patients),
while in the latter was 7.5% (34 out of a total 452 patients)
(p=0.96). Eight of these 10 studies involved comparison with
doxycycline-rifampicin [10,11,17,18,20,25,26,29], two compared
this regimen with doxycycline and gentamicin [27,28] and one
included a comparison with rifampicin and ofloxacin [26]. In all
these studies doxycycline-streptomycin combination was superior
or equal than the other compared regimens. The average time
until the disappearance of fever in all these 10 studies was less than
a week.
There are only 4 studies on the combined use of doxycycline
and gentamicin in adults. Hasanjani et al. published the results of
two comparative studies of doxycycline and gentamicin with
doxycycline and streptomycin [27,28]. In the first one, doxycycline
for 45 days plus gentamicin for 7 days of was compared with
doxycycline for 45 days plus streptomycin for 14 days. In the
second study published in 2010 [28], doxycycline treatment was
extended to 8 weeks and combined with 5 days of gentamicin, and
this treatment was again compared with doxycycline for 45 days
plus streptomycin for 14 days. In none of the studies was any
advantage noted for the combinations including gentamicin
instead of streptomycin.
Solera et al performed 2 studies [31,32] comparing doxycycline
for 30 or 45 days with fixed treatment duration of 7 days for
gentamicin. The first study was non-randomized and included
fewer patients. The second study, published in 2004, was a
randomized double-blind study and included not only a
comparison of the two treatment durations but also an analysis
of relapse risk factors. The results of the two studies were in favor
of the administration of doxycycline for 45 days. In the study of
relapse risk factors, the significant factor was in fact the shorter
treatment time.
Although in a non-comparative study, other combination
including aminoglycosides that has been tested is doxycycline plus
netilmicin [33]. This regimen resulted in a high rate of relapse
(12.5%) and therapeutic failure (7.7%).
There has only been one small non-comparative study in 10
patients [34] to investigate azithromycin instead of doxycycline for
21 days in combination with gentamicin for the first 7 days. Three
out of 10 patients experienced relapse, treatment failed in 2, and
treatment had to be withdrawn in the case of one patient due to
side effects.
Only one study investigated triple therapy with doxycycline,
rifampicin and amikacin [16] in patients with uncomplicated
brucellosis, with the aminoglycoside being administered for 1 week
and the other two antimicrobials for a total of 8 to 12 weeks.
Comparison was made with the regimen of doxycycline and
rifampicin administered together for 8 to 12 weeks. No significant
differences between the two combinations were observed regard-
ing relapse (6 cases, i.e. 5.7%, of relapse with triple therapy vs. 9
cases, i.e. 9.3%, with combined doxycycline-rifampicin; p=0.4).
However, differences were observed in terms of resolution of
symptoms (fever, arthralgia, shivering) but with only borderline
statistical significance (p=0.04, CI 95%: 0.008–0.15). This
difference is more pronounced when fever is taken as a symptom
(although the study does not specify what temperature constitutes
fever) and comparisons of number of patients with fever 2 weeks
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after two weeks with doxycycline and rifampicin vs. 7.8% of
patients on the triple therapy. In addition, there is a discrepancy
between the time to defervescence described in the text and that
shown in the graph published in the study, which suggests that
over 50% of patients presented fever after two weeks of treatment.
This high percentage of patients with fever after two weeks of
treatment was not seen in any of the other studies investigating
combined doxycycline and rifampicin [8,17–22].
Triple therapy was administered in two other studies [15–25],
however, they involved only patients presenting osteoarticular
brucellosis. Bayindir et al. [15] carried out a study in patients with
brucella spondylitis. Twenty two patients receiving combined
rifampicin and doxycycline for 45 days, together with streptomy-
cin over the first 15 days were included in the study and the results
were extremely good regarding relapse and treatment failure, with
a 100% response rate and no relapses. In the second study,
conducted in Egypt [35] in patients presenting osteoarticular
brucellosis, dual therapy comprising rifampicin and either co-
trimoxazole or doxycycline was compared with triple therapy
comprising doxycycline, rifampicin and streptomycin. Although
the results of the last combination were superior, multivariate
analysis showed that treatment duration (less than 5 months) was
the variable truly predictive of relapse. Despite this and the
limitations of the study in terms of treatment allocation, the
authors recommend triple therapy in the conclusion to their
article.
Combinations of orally-administered drugs. The
regimen combining rifampicin and tetracycline is the most
common in clinical trials of human brucellosis, with 20 studies
investigating this type of regimen [8,10,11,16–22,25,26,29,30,36–
41]. Nine of these studies compared this regimen with one of
tetracycline plus streptomycin, and 6 studies [19,21,22,26,37,38]
compared the combination of rifampicin with a quinolone. Two
studies compared this regimen with doxycycline and a quinolone
[36,38]. One of these studies compared it with monotherapy
involving ciprofloxacin, although in less than 10 patients per
regimen [41]. Another study involved minocycline instead of
doxycycline but this was a retrospective study [40]. The study by
Lubani et al. [30] was conducted only in children. Alavi et al. [39]
compared this regimen with combined doxycycline and
trimethoprim/sulfamethoxazole. Finally, the only study
comparing doxycycline and rifampicin vs. triple therapy with
rifampicin, doxycycline and amikacin is the previously indicated
work of Ranjbar et al. [16]
In general, less satisfactory results were obtained in comparison
with combined streptomycin and doxycycline, with relapse and
treatment failure rates of over 20% in certain studies, although the
results of the various studies were highly disparate. Relapse rates
ranged from 38.8% described by Ariza et al. [8] with administra-
tion of this combination for 30 days to 3.3% reported by Akova et
al. [19] following administration of the regimen for 6 weeks.
However, other authors using this combination for 45 days
reported a higher relapse rate than Akova, with Solera et al. [20]
indicating a 16% relapse rate and an 8% treatment failure rate.
Time to defervescence with this regimen was less than a week in
almost all cases (Table S1), and it was the best-tolerated regimen,
with treatment withdrawal for adverse drug effects being
extremely rare.
Only three studies investigated combined co-trimoxazole and
tetracyclines, two in adults [42,39] and one in children [30]. The
study by Hasanjani et al. [42] reported better results for
tetracycline and co-trimoxazole (8.6% relapse and 7.1% treatment
failure) than with rifampicin and co-trimoxazole (p=0.646 for
relapse, p=0.02 for treatment failure, and p=0.028 for the
combined variable of relapse and treatment failure). Alavi et al [39]
compared combined doxycycline and co-trimoxazole with com-
bined doxycycline and rifampicin in a population of nomadic
patients in Iran. The relapse and treatment failure rates with
doxycycline and co-trimoxazole were 5.88% and 1.94% respec-
tively. With doxycycline and rifampicin, the corresponding rates
were 11.76% and 9.81% respectively. The difference with regard
to the combined variable for relapse and treatment failure
obtained was p=0.05. Finally, Lubani et al. [30] obtained
excellent results with this combination in their study in children,
with an overall relapse rate of 4.9%, and no treatment failures for
therapy lasting 8 weeks.
Only three studies were performed with combined co-
trimoxazole and rifampicin: two in children [30,43], and one in
adults [42]. In 2004, Hasanjani et al. [42] published a study in 280
patients aged 10 and over (range: 10 to 81 years) comparing co-
trimoxazole and rifampicin vs. co-trimoxazole and doxycycline
(140 patients in each group). Co-trimoxazole and rifampicin were
administered for two months with a high rate of treatment failure
(16.4% failures, 10% relapses). In 2006, the same author
investigated this regimen [43] in 130 children divided in two
groups, one treated for 6 weeks and the other for 8 weeks. The
results were superior to those in the previous study and the
combined variable of relapse and treatment failure rate was lower
in the 8-week group (4.5%). Such good results in children had
been previously reported by Lubani [30] in 1989. In this study 34
children received this regimen with a global relapse rate of 5.88%,
but it should be noted that patients experiencing relapse had
received treatment for less than 6 weeks.
Six studies [19,21,22,26,37,38] combined quinolone and
rifampicin. In two [21,38] the quinolone was ciprofloxacin, and
in both it was compared to doxycycline and rifampicin, with the
quinolone yielding the least satisfactory results. In the remaining
four studies [19,22,26,37], the quinolone used was ofloxacin.
Results were disparate, although superior to those obtained with
ciprofloxacin, and with a relapse rate of approximately 10%. In
both studies comparison was made with combined doxycycline
and rifampicin. In the remaining studies considered separately,
with the exception of a study by Akova et al. [19], the results for
ofloxacin and rifampicin as regards relapse and treatment failure
rates were similar to those obtained with doxycycline and
rifampicin.
Two studies investigated this regimen in patients presenting
brucellar spondylitis. Bayindir et al. [15] administered ofloxacin
and rifampicin for 45 days to 19 patients with spondylitis, with
poor results, comprising a treatment failure rate of 26% and a
26% relapse rate. Alp et al. [44], administered ciprofloxacin and
rifampicin for a minimum of 12 weeks, with better results. A 100%
response rate was achieved with no relapses, although the authors
reported 2 and 9 patients having moderate and mild sequelae,
respectively.
Only two comparative studies assessed quinolone-doxycycline
combination [36,38], and in both the quinolone was ciprofloxacin.
In the first study [36] in of 12 patients, only one patient relapsed
(8.33%) with no treatment failures. In the second [38], the results
were inferior to those with doxycycline and rifampicin or with
ciprofloxacin and rifampicin, with a relapse rate of 17.5% vs. 7.7%
and 8.3% respectively, but with p=0.35. However, the data for
the doxycycline-quinolones treatment are very scarce and its
inferiority versus quinolone-rifampin is not evident.
Monotherapy. Very few comparative studies were found that
assess of monotherapy [9,25,30,41,45] and they included only a
small number of patients.
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failure and relapse [9,25,30] were recorded. Ariza et al. [9] carried
out a study comparing monotherapy with co-trimoxazole for 45
days vs. combined tetracycline for 21 days and streptomycin for
the first 14 days. The relapse rate was 46.6% in the co-trimoxazole
group vs. 14.8% in the tetracycline-streptomycin group (p,0.05).
In the study by Montejo et al. [25], 64 patients received co-
trimoxazole for 6 months, with an 81.25% cure rate. In over 18%
of the patients a change of treatment was required due to side
effects (3.1%), treatment failure or non-completion (12%) and
relapse (3.1%).
The study by Lubani et al. [30] included 161 children treated
with co-trimoxazole, but the relapse rate was 29.8% no matter
whether the, treatment period was 3, 5 or 8 weeks.
The three studies performed with tetracyclines were those by
Feiz et al. [46], Lubani et al. [30] and Montejo et al. [25]. That of
Feiz [46] in Iran was published in 1973 and it thus lies outside the
timeframe of our study. Nevertheless Feiz reported a 31% relapse
rate in patients treated with oxytetracycline and a 29% relapse rate
in those treated with doxycycline, although the treatment period
was very short, lasting only 21 days. Moreover, the dose was
reduced to half the initial dose 14 days after the beginning of
treatment in the doxycycline group. These two circumstances
make difficult to compare this work with subsequent studies.
As indicated above, the study by Lubani et al. [30] was
conducted in children, and also tested two regimens, one with
oxytetracycline and the other with doxycycline. The results were
far superior to those reported by Feiz, and relapse rates proved to
be inversely proportional to treatment time, a finding that was
much clearer with this regimen than with others used in the same
study. Thus, the relapse rate dropped to 0% when the treatment
was extended to 8 weeks.
The third study published was that of Montejo et al. [25] in
1993. For the purpose of the study, a daily dose of 200 mg
doxycycline was administered constantly during the six weeks of
treatment. Seventy-one patients were included, with a relapse rate
of 14.08%. Since then, no other studies on monotherapy with
tetracyclines have been published.
The results of the study published in 1987 by Grasso et al. [47]
in Italy are also worth commenting, even though it is a
retrospective non-comparative study. It was performed in 295
patients with brucellosis treated with minocycline. While 116
patients received a single course for 35 to 40 days, 82 others
received two courses of minocycline lasting 35 and 15 days with a
15-day pause between cycles, and the remaining 97 patients
received it with a vaccine. In all cases, the dose was 100 mg/
12 hours. The overall number of patients presenting relapse was
10 (3.38%). One patient died due to hepatic failure not clearly
related to the treatment received in the study. The authors
compared these results with those obtained in another sample of
179 patients treated with doxycycline in which the relapse rate was
5.17%. However, this study exhibits the limitations of a
retrospective study, and furthermore, no clear details are offered
of total patient follow-up time.
The only prospective, comparative and randomized study with
quinolone monotherapy was published in 1990 by Lang et al. [41].
This was a small study in 6 patients with brucellosis treated with
ciprofloxacin for 42 days. The comparison was established with 4
other patients treated with doxycycline and rifampicin. Relapse
occurred in 5 of the 6 patients treated with ciprofloxacin.
Subsequently, no comparative randomized studies of quinolones
as monotherapy have been published. In 1991, Khuri-Bulos and
Shaker [48] published a small study in 5 patients each receiving
200 mg ofloxacin every 12 hours for 21 days. Relapse occurred in
3 of the patients. Doganay and Aygen [49] published a small non-
comparative study in 1992 in 14 patients receiving 500 mg
ciprofloxacin every 12 hours for 3 to 6 weeks. Three exhibited
relapse (21.4%) and one patient presented endocarditis and died 5
months later. Al Sibai et al. [50] carried out another non-
randomized prospective study in 1992 in 16 patients treated with
ciprofloxacin for 6 to 12 weeks, with a relapse rate of 27%.
Rifampicin was used as monotherapy in several studies. The
largest of these was the already-mentioned study by Lubani et al.
[30], with positive results in children. Few other studies have been
published [51] and only in small numbers of patients. The risk of
inducing resistance of tuberculosis to rifampicin is likely to have
curbed the implementation of such studies.
Two studies were performed with ceftriaxone [45,52] in a small
number of patients and with poor results. That of Lang [45] was a
small comparative study in only 8 patients receiving ceftriaxone,
and the treatment failure rate was 75% (6 patients). Al Idrissi [52]
carried out a non-comparative study, also with a very high
treatment failure rate (30.8%).
Comparisons between regimens used in randomized
clinical trials
The comparisons of regimens that can be established with the
randomized clinical trials published in the past 25 years are as
follows: doxycycline and streptomycin vs. doxycycline and
rifampicin, 9 studies; doxycycline and streptomycin vs. doxycycline
and gentamicin, 2 studies: doxycycline and rifampicin vs.
quinolone and rifampicin, 6 studies; doxycycline and rifampicin
vs. ofloxacin and rifampicin, 4 studies; and doxycycline and
rifampicin vs. doxycycline and quinolone, 2 studies. Since there
was only one study [16] using doxycycline, rifampicin and
aminoglycosides vs. other regimens in patients with uncomplicated
brucellosis, no conclusions can be drawn on the value of this triple
therapy. Other studies using this triple therapy were performed
only in patients with brucellosis involving osteoarticular compli-
cations and, since the importance of these regimens might be
overestimated, it seems unsuitable to extrapolate such data to
patients with acute non-focal brucellosis. In addition, the only
monotherapy on which more than one randomized study was
performed was with co-trimoxazole, and the results show a high
relapse rate [9,25]. The only comparative randomized study with
tetracyclines in adult patients in monotherapy published in the
past 25 years is that of Montejo [25]. The study by Feiz [46],
besides being outside the timeframe of our review, is not
comparable with the study by Montejo in terms of either dosage
or treatment duration.
The study by Acocella et al. [10], which is important for the
comparison of doxycycline-streptomycin vs. doxycycline-rifampi-
cin, included 3 groups. One group was treated with tetracycline for
21 days and streptomycin for 14 days. This regimen is not
comparable with others using doxycycline 45 days because of the
shorter tetracycline treatment. Thus, the comparison of doxycy-
cline-streptomycin vs. doxycycline-rifampicin included only the
other two groups in the study, which received these two regimens.
The results of the comparison between doxycycline-streptomy-
cin and doxycycline-rifampicin favor the first combination in
terms of relapse (OR=3.52; CI95%=2.14–5.81; p,0.001;Ro-
senthal index 57; I
2=0%) and of the combined variable of relapse
and therapeutic failure (OR=3.17; CI95%=2.05–4.91; p,0.001;
Rosenthal index=64; I
2=0%) (figure 2 and figure S1).
The difference in the comparison between doxycycline-
streptomycin and doxycycline-gentamicin is not statistically
significant as regards either relapses (OR=1.65; CI95%=0.53–
5.15; p=0.38621; I
2=0%), or the combined variable of relapse
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0.14106; I
2=0%).
The comparison of doxycycline-rifampicin vs. rifampicin-
quinolone shows no significant differences neither for relapse
(OR=1.11; CI95%=0.53–2.34; p=0.77) nor for the combined
variable of relapse and treatment failure (OR=1.23; CI95%
=0.63–2.40; p=0.55; I
2=0%) (figure 3). The comparison of the
doxycycline-rifampicin regimen with the four studies involving
ofloxacin-rifampicin shows no differences (for relapse and
treatment failure: OR=1.06; CI95%=0.45–2.5) (figure 4).
Finally, the comparison of doxycycline-quinolone vs. doxycy-
cline-rifampicin favors doxycycline-rifampicin (OR=3.92;
CI95%=1.35–11.42; p=0.01). When comparing combined
regimens containing quinolones (whether doxycycline-quinolone
or rifampicin-quinolones) with combined doxycycline-rifampicin,
the OR=1.33 for relapse was not statistically significant
(CI95%=0.67–2.63; p=0.42; I
2=0%). As regards the combined
variable of relapse and treatment failure, the result was similar
(OR=1.59; CI95%=0.87–2.91; p=0.14; I
2=0%).
Side effects
The side effects of the standard medication were mild or
moderate, and only rarely serious and requiring treatment
withdrawal. Not all authors reported side effects, and these were
not uniformly evaluated in all cases. The numbers of side effects
reported are shown in Table 1.
Where comparison was possible using data from the separate
randomized comparative studies, the only differences concerning
side effects were noted in the comparison of doxycycline-
rifampicin vs. rifampicin-quinolones, with the result in favor of
the latter combination (OR=0.27; CI95%=0.15–0.50;
p,0.0001; I
2=0%; Rosenthal index=18) (Figure 5).
Seven of the studies that compared between doxycycline-
streptomycin and doxycycline-rifampicin considered side effects.
In this respect, the doxycycline-streptomycin regimen has not
advantage, whether we consider the side effects in general
(OR=1.13; CI95%=0.58–2.18; p=0.73; I
2=63% p=0.01;
random effects method) or the serious side effects (OR=1.52;
CI95%=0.44–5.29; p=0.51). Analysis of side effects in general
showed heterogeneity among studies. This heterogeneity is due to
the presence of two groups of studies in which side effects were
considered. In a group of four studies [8,10,11,17], the comparison
favours doxycycline and rifampicin (OR=0.52; CI95%=0.27–
0.99; p=0.05) while a second group of three studies [18,20,26]
favors the doxycycline-streptomycin combination (OR=2.08;
CI95%=1.32–3.27; p=0.002).
There were no significant differences in side effects between
doxycycline-streptomycin and doxycycline-gentamicin (OR=
0.74; CI95%=0.46–1.19; p=0.22).
Treatment duration
The relapse and treatment failure rates by regimen and by
treatment duration are shown in Table 2.
All trials involving doxycycline and streptomycin involved a
treatment duration of six weeks. The only difference here concerns
the duration of treatment with streptomycin, which in two
Figure 2. Relapses and treatment failure with doxycycline and rifampicin vs. doxycycline and streptomycin regimens in treatment
of human brucellosis.
doi:10.1371/journal.pone.0032090.g002
Figure 3. Relapses and treatment failure with quinolone-rifampicin regimen versus doxycycline and rifampicin regimen in
treatment of human brucellosis.
doi:10.1371/journal.pone.0032090.g003
Systematic Review: Treatment of Human Brucellosis
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32090publications [25,26] was three weeks rather than the standard two
weeks. However, this prolonged parenteral treatment was not
clearly beneficial in terms of results.
Regarding combined doxycycline and gentamicin, it may be
concluded that treatment with doxycycline for 45 days yields
superior results to 30 days of treatment [31,32]. Abramson et al.
[53] investigated a short course of treatment in 10 children aged
between 8 and 16 with gentamicin for 5 days and doxycycline for 3
weeks, with a high rate of relapse and treatment failure (3 patients:
30%). In contrast, in a recent study [28], treatment was
maintained for 8 weeks with doxycycline and gentamicin, but no
clear advantages were observed compared with 45 days of
treatment (figure 6).
Similar results were found for the doxycycline-rifampicin
regimen (figure 6). The majority of authors continued antibiotic
therapy for 45 days. Only two [8,25]shortened the treatment to one
month, with clearly inferior results (Table 2). Solera et al. reduced
the treatment time with rifampicin to 21 days, maintaining
doxycycline for 45 days, but this also yielded poor results [17].
In the studies combining rifampicin and quinolone, a 30-day
treatment duration yielded a higher relapse rate than a 45-day
treatment duration, no matter whether the quinolone was
ciprofloxacin (8.3% relapses in Keramat et al. [38], with 8 to 12
weeks of treatment vs. 15% in Agalar et al. [21] with 30 days of
treatment) or ofloxacin (the highest relapse rate with this quinolone
was seen in Karabay et al. [22]: 13.3% for 30 days of treatment).
The results obtained by Feiz [46] following 21 days of treatment
with tetracyclines show a very high relapse rate, but these results
were better after 45 days of treatment in the study by Montejo et al.
[25]. Lubani et al. [30] showed that the results shows no significant
differences dependent on treatment time in children.
There were only two comparative randomized studies compar-
ing similar regimens but with different treatment durations. One of
these studies is that by Acocella et al. [10], comparing doxycycline
for 45 days and streptomycin for 14 days vs. tetracycline for 21
days and streptomycin for 14 days. Montejo et al. [25]
administered streptomycin for 14 or 21 days with 45 days of
doxycycline, and doxycycline and rifampicin for 4 or 6 weeks.
Figure 4. Relapses and treatment failure with ofloxacin and rifampicin versus doxycycline and rifampicin in treatment of human
brucellosis.
doi:10.1371/journal.pone.0032090.g004
Table 1. Side effects reported in different studies in the treatment of non-focal human brucellosis.
Regimen N6 of studies [references] N6 patients




Tetracycline + streptomycin 2 [8,10] 55 8 (14.5%) 1 (1.8%)
Doxycycline + streptomycin (15 days) 8 [10,17,18,20,24,25,27,28] 591 98/551 (17.8%) 5 (0.8%)
Doxycycline + streptomycin (21 days) 3 [11,25,26] 135 15/91 (16.5%) 0
Doxycycline (30 days)+ gentamicin 2 [31,32] 108 43 (39.8%) 0
Doxycycline (45 days)+ gentamicin 3 [27,31,32] 187 60 (32.1%) 0
Doxycycline ($56 days)+ gentamicin 1 [28] 82 25 (30.5%) 0
Triple therapy 1 [16] 110 6 (5.5%) 0
Doxycycline + rifampicin (28–30 days) 2 [8,25] 83 1/18 (5.6%) 0
Doxycycline + rifampicin (42–45 days) 12 [10,11,17–22,25,26,36,37] 482 103/406 (25.4%) 6 (1.2%)
Doxycycline + rifampicin ($56 days) 3 [16,38,39] 224 14/171 (8.2%) 2 (0.9%)
Rifampicin + cotrimoxazole 1 [42] 140 ---------- 7 (5%)
Tetracycline + cotrimoxazole 1 [42] 140 ---------- 2 (1.4%)
Rifampicin + ciprofloxacin 2 [21,38] 82 4 (4.9%) 0
Rifampicin + ofloxacin 4 [19,22,26,37] 114 14/87 (16.1%) 1(0.9%)
Doxycycline + quinolone 1 [38] 55 9 (16.4%) 0
Cotrimoxazole 1 [25] 64 ---------- 2 (3.1%)
Doxycycline 1 [25] 71 ---------- 1 (1.4%)
Quinolones 1 [50] 16 7 (43.7%) 0
doi:10.1371/journal.pone.0032090.t001
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studies.
Dose
The dosage of drugs used was fairly uniform throughout the
various studies. For doxycycline, streptomycin and gentamicin, the
dose used was similar in all trials. The only study that used two
distinct doses of the same drug sequentially was that of Feiz [46], in
whichseparate doseswereusedinmonotherapywithoxytetracycline
and with doxycycline. The high relapse rate observed in this study
could be due to either this change of dosage or to the brief duration
of treatment (only 21 days). For rifampicin, doses of 600 and 900 mg
per day (in certain studies a dose of 15 mg/kg bodyweight was
stipulated) were used in combination with doxycycline, but no clear
differences were observed between the results of the different studies.
Mortality
The data provided by the various studies, whether including
trials or series of clinical case reports (Table 3), show that the
mortality associated with brucellosis is very low. No deaths were
reported in the randomized studies, and in the case reports which
we examined, only 6 deaths were reported for over 1500 cases of
brucellosis (,0.4%). However, in some studies, conducted
primarily in developing countries, initial treatment involved
hospitalization (Tables S1, S2 and 3).
Time to defervescence
Another data item used in the studies is time to defervescence.
Although this time varied in all publications, it was under a week in
practically all cases, and in most less than 5 days (Tables S4 and S5).
Malik [54] published a study that included a retrospective analysis of
73 patients diagnosed with brucellosis in a hospital in Saudi Arabia
between 1987 and 1994. The mean defervescence time was
4.3261.47 days, with no differences between treatment groups.
Data were also provided concerning the duration of the hospital stay,
which was 7.7562.12 days. In the study of Aygen et al. [55], among
the 187 patients with fever, the average time to defervencence for all
treatments regimens was less than 7 days (range: 2 to 15 days).
Figure 5. Side effects with combined rifampicin and quinolone versus combined doxycycline and rifampicin in patients with human
brucellosis.
doi:10.1371/journal.pone.0032090.g005
Table 2. Percentage, by regimen and treatment duration, of relapses and therapeutic failures reported in different studies in
treatment of non-focal human brucellosis.
Regimen N6 of studies patients relapses failures
Relapses +
failures
TETR (21 days)+STP 2 [46,10] 55 16.4% 9.1% 25.5%
TETR (30 days) + STP (21 days) 1 [8] 28 7.1% 0% 7.1%
DX(45 d)+STP(15 d) 8 [10,17,18,20,24,25,27,28] 591 4.2% 3.4% 7.6%
DX (45 d) +STP(21 d) 3 [11,25,26] 135 5.2% 1.5% 6.7%
DX (30 days) + G 2 [31,32] 108 21.3% 0% 21.3%
DX (45 days) + G 3 [31,32,27] 187 6.9% 1.1% 8.02%
DX (56 days or more) +G 1 [28] 82 2.4% 2.4% 4.9%
DX + RF (28–30 days) 2 [8,25] 83 25.3% 1.2% 26.5%
DX+ RF (42–45 days) 12 [10,11,17–22,25,26,36,37] 494 12.1% 3% 15.2%
DX+RF (56 days) 3 [16,38,39] 222 7.7% 9% 16.6%
RF + OFX (30 days) 1 [22] 15 13.3% 0% 13.3%
RF+ OFX (42–45 days) 3 [19,26,37] 99 8.1% 2% 10.1%
DX + TMP/SMX (adults) 2 [42,39] 191 7.9% 5.8% 13.6%
RF + TMP/SMX (adults) 1 [42] 140 10% 16.4% 26.4%
DX (adults) 21 days 1 [46] 31 29% 0% 29%
DX (adults) 42 days 1 [25] 71 14.08% 0% 14.08%
Abbreviations: DX=doxycycline; RF=rifampicin; TETR=tetracycline u oxitetracycline; STP=streptomycin; G=gentamicin; TMP/SMX=cotrimoxazole; OFX=ofloxacin.
doi:10.1371/journal.pone.0032090.t002
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Studies including over 100 patients published in the past 10 years
are showninTable3.Thesestudiesincluderegimensforwhichthere
are no studies demonstrating efficacy. Thus, Barroso etal. [56] report
the use of triple therapy comprising tetracycline, streptomycin and a
sulphonamide. Bosilkovski et al. [57] report the use of doxycycline
with rifampicin and gentamicin. Memish et al. [58] report the use of
combined tetracycline, rifampicin and streptomycin.
The study by Aygen et al. [55] of 480 cases is significant, since it
shows the high relapse rate in patients receiving ciprofloxacin,
whether as monotherapy or in combination. Other studies [59–62]
are included in table 3.
In these series of patients, fewer cases of relapse were observed
than in randomized clinical trials, probably as a result of the closer
follow-up of patients included in clinical trials.
Discussion
Even though effective antibiotics for brucellosis are available,
the problem of treating this disease has not been completely
solved. The most widely used and recommended regimens are
those combining doxycycline and an aminoglycoside or rifampici
n. Other regimens that have demonstrated efficacy in different
studies are combinations of quinolones and rifampicin, co-
Figure 6. Relapses and therapeutic failures with the combined doxycycline-gentamicin regimen and doxycycline-rifampicin
regimen reported by treatment duration.
doi:10.1371/journal.pone.0032090.g006
Table 3. Results of brucellosis therapy in large patient series.
Author (year) [ref] country
Years of
study N6 cases Therapeutic regimens relapses Failures mortality
Hospital
admission
Barroso Garcia P (2002)
[56]
Spain 1972–1998 1595 TETR+STP ; TETR+STP+ Sulphonamide ;
DX+STP ; STP+Sulphonamide+DX ;
TETR
NR NR NR No
Andropoulos (2007) [59] Greece 1990–2003 144 DX+STP (.14 an ˜os);
RF+TMP/SMX (nin ˜os)
4 (3%) NR 0 Yes
Bosilkovski (2007) [57] Macedonia 1998–2004 418 DX+RF+TMP/SMX ; DX+RF ; DX+RF+G 16.2% 10.4% 1 Yes (until
improvement)
Aygen (2002) [55] Turkey 1989–1998 480 DX+RF; DX+STP; TETR+STP; CPX 26 (5.4%) 0 3 NR
Memish (2000) [58] Saudi Arabia 1983–1995 160 TETR+STP; DX+RF; TETR+STP+ RF;
RF+TMP/SMX; RF+STP+TMP/SMX
7 NR 0 Yes
Buzgan (2010) [65] Turkey 1998–2007 1028 DX+RF (most used); DX+STP;
DX+RF+STP; DX+CPX; RF+TMP/SMX;
RF+CPX
4.7% NR NR Yes (2–3 weeks)





8 NR 1 Yes
Savas l (2007) [61] Turkey 2000–2002 140 DX+RF; DX+STP; RF+CPX; DX+RF+STP;
RF+TMP/SMX
5 NR 0 Yes(37 patients)
Demirturk (2008) [62] Turkey 2002–2006 99 DX+RF; DX+RF+CPX 0 (of 30 cases
with follow up)
0 1 Yes
TETR=tetracycline, STP=streptomycin, DX=doxycycline, RF=rifampicin, TMP/SMX=cotrimoxazole, G=gentamicin, CPX=ciprofloxacin.
doi:10.1371/journal.pone.0032090.t003
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rifampicin and aminoglycoside. In addition, observational studies
in large series of patients [55–57] show that regimens other than
those recommended continue to be used like, for example,
doxycycline, rifampicin and co-trimoxazole, rifampicin and
ciprofloxacin, doxycycline and ciprofloxacin, or regimens based
on antibiotics used in monotherapy [58].
Therefore, finding a unique response in the treatment of
brucellosis is not an easy task. In our review, we concentrated on
acute non-focal brucellosis. Our intention in this study was to
investigate, through a review of published data, the possibilities of
different regimens, representing an alternative to those recom-
mended most frequently. With these data we sought to answer the
most important questions concerning the treatment of human
brucellosis and which we posed at the end of the introduction:
what is the most effective regimen, what alternative regimens are
there, whether triple therapy may be recommended as the best
option, whether monotherapy represents a valid alternative, and
what treatment duration should be recommended. We also sought
to identify new fields of research in view of current knowledge and
the complexity of this disease.
Based on the studies performed to date, we may conclude that
the regimen combining doxycycline and streptomycin has been
shown to be superior to combined doxycycline and rifampicin, in
terms of both relapse rate (OR=3.52; CI95%=2.14–5.81) and
combined relapse-treatment failure (OR=3.17; CI95%=2.05–
4.91). No advantages emerged regarding side effects in view of the
heterogeneity of the various studies in this respect. No significant
differences were obtained with combined doxycycline and
gentamicin to combined doxycycline and streptomycin, which
has been the most widely-used aminoglycoside.
In spite of these findings, the need for parenteral administration
of aminoglycosides may complicate the use of this regimen,
primarily in those parts of the world where lack of healthcare
personnel is a limiting factor [63]. In a recent study [64], 64.6% of
healthcare professionals interviewed preferred the doxycycline-
rifampicin regimen, despite the demonstrated superiority of
streptomycin-doxycycline. Furthermore, in a recent large series
involving over 1000 patients [65], the most frequently-used
regimen was doxycycline-rifampicin. Indeed,combined rifampicin
and doxycycline also poses problems in developing countries due
to its potential to induce resistance to rifampicin in other
infections, mainly in tuberculosis.
The only study involving triple therapy in patients with acute
uncomplicated brucellosis is that of Ranjbar [16], which
investigated combined doxycycline, rifampicin and amikacin.
Amikacin was administered parenterally for one week, and the
other two antibiotics for 8–12 weeks. This regimen, which is longer
than the standard treatment, is potentially disadvantageous in
terms of therapeutic adherence and cost. Furthermore, a
comparison was made with combined doxycycline-rifampicin,
and no clear differences were observed concerning therapeutic
efficacy. The conclusions were based on the disappearance of fever
after two weeks of treatment, a time extremely long for evaluating
the clinical response which, as already stated, occurred in all
studies within the first few days of the start of treatment [56,66].
Other studies of triple therapy were performed in patients
presenting osteoarticular brucellosis [15,35], and therefore the
conclusions of these studies cannot be extrapolated to patients with
uncomplicated brucellosis. As a result, this triple therapy cannot be
recommended as the treatment of choice for human brucellosis
until data supporting its usefulness is obtained in randomized
clinical trials.
Combined rifampicin and quinolone appears to offer a valid
alternative, with efficacy comparable to that of combined
doxycycline and rifampicin in terms of both relapse (OR=1.11;
CI95%=0.53–2.34) and combined relapse-treatment failure
(OR=1.23; CI95%=0.63–2.40). In addition, comparison of side
effects favors the regimen with quinolone (OR=0.27;
CI95%=0.15–0.50). However, no statistical significance was
noted when comparing combined doxycycline-quinolone with
doxycycline-rifampicin. However, most studies with quinolones
have been made in the same group of countries and some of them
include a small number of patients. Consequently, although the
results obtained indicate that quinolones could be an alternative to
doxycycline plus rifampicin, the recommendation of its use may
require further studies.
Skalsky et al. [14] advise against the use of regimens involving
quinolones. However, the results of their meta-analysis are
compromised by the inclusion of the study by Bayindir [15],
which was performed solely in patients with osteoarticular
brucellosis. It seems premature to extrapolate the results of this
study to non-focal brucellosis.
There are very few studies evaluating the efficacy of other
regimens and, while the scarce available data do not allow to
recommend these regimens, they could improve compliance and
facilitate administration of treatment as they involve oral
administration and are of similar duration to those already in
use. Thus, a combined regimen of co-trimoxazole and doxycy-
cline, for example, yielded good results in the two studies in which
it was used in adults [39,42]. Combined rifampicin-co-trimoxazole
yielded good results in children [30,43], although this regimen
poses the risk of inducing resistance to rifampicin and did not yield
good results in adults [42].
Since the end of the 1940s, when combined antibiotics began to
be used to treat human brucellosis, monotherapy was relegated to
a second place and its use has been repeatedly rejected in many
publications [14]. Although it is true that co-trimoxazole,
rifampicin or quinolones in monotherapy have not yielded good
results, this conclusion cannot be extended to doxycycline. The
study by Montejo et al. [25] reported results with doxycycline in
monotherapy similar to those obtained with other regimens
recommended by the World Health Organization. Despite this, no
other studies have been performed with doxycycline in mono-
therapy and, consequently, these results cannot be compared with
new data.
Although the meta-analysis by Skalsky et al. [14] includes seven
studies involving monotherapy, they had different characteristics.
It compared monotherapy and combined therapy with a similar
duration of treatment but combines studies with very different
monotherapies such as co-trimoxazole or tetracyclines. This
author also rejects monotherapy with tetracyclines based on two
studies: the study by Montejo et al. [25], mentioned previously and
the study by Feiz et al. [46], which was not comparable to the
former because of the previously explained factors. In spite of this,
the relative risks (RR) described are not statistically significant
compared with monotherapy using tetracyclines [RR for the
combined variable of relapse and treatment failure of 1.01
(CI95%=0.58–1.77) and RR for therapeutic failure of 0.25
(CI95%=0.03–2.32)]. Therefore we feel that the use of doxycy-
cline alone in the treatment of human brucellosis cannot be
dismissed on the basis of current data, and that there is a need for
further studies involving this regimen.
Since only a very small number of studies compared similar
regimens administered over different periods, it is difficult to draw
any conclusions concerning treatment duration. A duration of 45
days was superior to 30 days for combined doxycycline-
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the doxycycline-rifampicin regimen, most authors continued
treatment for 45 days. The data from these studies suggest that
shorter treatment periods yield inferior results, while longer
periods do not offer clear advantages (Table 2). Consequently, 6
weeks seems advisable. In a retrospective study [47], an
intermittent treatment regimen was reported, but there are no
studies to support this regimen.
So far, no studies have examined the cost-efficiency of
treatments of human brucellosis. Most studies conducted before
the 1990s were conducted in Western countries where preventive
measures have succeeded in eradicating the disease and where a
health system is in place with sufficient resources for patient care.
Currently, brucellosis has become a disease in countries with a
lower capacity for medical assistance [1,63] as a result of the
scarcity of healthcare professionals and resources to cover the rural
areas and the characteristics of the population often nomadic.
These circumstances could account for the greater use of oral drug
regimens. Similarly, the difficulty of ensuring satisfactory admin-
istration of treatment and adequate follow-up because of economic
or cultural reasons could account for the high percentage of studies
involving initial treatment in patients following hospitalization,
which results in a considerable increase in expenditure.
In 2002, Straight and Martin [67] carried out a review in which
they reported the cost of the various drugs used to treat human
brucellosis, as well as the associated contraindications and side
effects. According to this review, trimethoprim-sulfamethoxazole is
the least expensive drug regimen, with a cost of USD 11.02 for 45
days of treatment, followed by doxycycline at USD 12.71 for 45
days of treatment. The most expensive drugs were the quinolones,
with an approximate treatment cost of USD 224.06 for 45 days of
treatment. Gentamicin was less expensive than streptomycin,
although for these two drugs the cost of parenteral administration
equipment must be added. The costs of treatment with these drugs
in Spain are shown in Table 4. The least expensive combination of
drugs is doxycycline and co-trimoxazole which, despite yielding
good results in the few clinical trials in which it was used and being
considered a cost-efficient combination by some authors [68], has
not achieved widespread use. Treatment with doxycycline as
monotherapy costs half as much as the least expensive combina-
tion, even if treatment is prolonged beyond 45 days. It would be
useful to carry out further studies to determine the efficacy of
doxycycline monotherapy in various groups of patients.
It would also prove useful to determine the cost-efficiency of the
different alternatives for the treatment of human brucellosis, taking
other factors into consideration such as availability of staff and
healthcare centers in the various regions and side effects. Studies
undertaken to determine the best form of treatment for these
patients should take into account social and economic factors [69],
and it is difficult to conduct such studies from the perspective of
countries where drug administration, follow-up, or availability of
antibiotics pose a problem.
The main limitation of any review of treatment for human
brucellosis is the scarcity of well-designed clinical trials. Only two
of the studies reviewed were in fact double-blind [18,32] and only
five had adequate allocation concealment [25,27,28,32,42]. Some
of these studies included only a small number of patients
[36,41,45], and most studies concerned the two main regimens:
combined doxycycline-rifampicin and combined doxycycline-
streptomycin. Studies to evaluate other combinations, such as
triple therapy, monotherapy with doxycycline, or other combina-
tions such as doxycycline and quinolones, were insufficient in
number to allow any definitive conclusionson their usefulness. In
addition, factors such as epidemiological conditions, different
criteria and type of clinical monitoring can influence the relapse
rate detected. Well design clinical trials are necessary to detect
differences in relapses between treatment groups that we have not
been able to find in this meta-analysis.
Another limitation is that of the degree in which the
recommendations are applicable. The fact that brucellosis is
endemic in developing countries means that, in many cases,
treatment choice is based on convenience with regard to socio-
Table 4. Cost of antimicrobial agents for treatment of human brucellosis in Spain [72].
Cost of antimicrobial agents
Antibiotic Time of therapy Dairy dosage (adults) Dairy cost Total cost of therapy
Doxycycline 45 days 200 mg 0.48 J 21.6 J
Tetracycline 45 days 2 g 1.16 J 52.2 J
Rifampicin 45 days 600–900 mg 0.78–1.17 J 35.1–52.65 J
Streptomycin* 14–21 days 1 g 2.17 J* 30.38–45.57 J*
Gentamicin* 7 days 5 mg/kg 3.62 J* 25.34 J*
Cotrimoxazole 45 days 480 mg/2400 mg 0.47 J 20.92 J
Ofloxacin 45 days 400 mg 1.36 J 61.22 J
Cost of combined regimens
Regimen Cost
Doxycycline 45 days +cotrimoxazole 45 days 42.52 J
Doxycycline 45 days + gentamicin 7 days 46.94 J*
Doxycycline 45 days + streptomycin 14 days 51.98 J*
Doxycycline 45 days + rifampicin 45 days 56.70–74.25 J
Doxycycline 45 days + ofloxacin 45 days 82.82 J
Ofloxacin 45 days + rifampicin 45 days 96.32–113.87 J
*This cost does not include the cost of syringes or intravenous equipment.
doi:10.1371/journal.pone.0032090.t004
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rates [64]. Brucellosis is a disease with low mortality, with a high
cure rate for oral treatment, and with episodes of relapse that
normally respond well to a further course of the same antibiotics.
Consequently, factors such as treatment costs should be taken into
consideration in future studies.
In addition, there are no studies to investigate the efficacy of the
various regimens depending on patient conditions, complications or
relapse risk. The published studies do not consider the possible
inclusion of patients with different risk profiles for poor outcome or
treatment inefficiency. Ariza et al. [70] carried out a study in which
the following independent risk factors for relapse were identified:
treatment with a ‘‘less effective’’ antibiotic, positive blood culture at
the start of treatment, duration of illness of 10 days or less before the
startoftreatment,male genderandplateletcountof150610
3/mlor
less. Solera et al. published a study [71] in which three risk factors
prior to treatment were identified as predictive of a poor clinical
outcome: fever of 38.3uC or more, positive blood tests at the outset,
and presence of symptoms for less than 10 days at the start of
treatment. A model may thus be defined in which patients may be
divided into three different groups according to risk of relapse: first,
a low-risk group having at least two of the aforementioned factors
with a risk of relapse within the year of 4.5%; second, an
intermediate-risk group (with two of the factors mentioned) having
a risk of relapse within the year of 31.9%; third, a high-risk group,
with three of the factors mentioned, having a risk of relapse of
66.7%.There have been nostudieswiththis stratificationofpatients
into risk groups to evaluate the efficacy of treatment for human
brucellosis. It is likely that patients with a lower risk of relapse are
candidates for simpler and shorter treatment, including monother-
apy.Thiswould be an interesting field of research that could change
the treatment of brucellosis, and it would be extremely useful
primarily in countries with limited resources where the rationali-
zation thereof bears the greatest importance.
Thus, we may conclude that we still face important challenges
in the investigation of treatment for human brucellosis. In view of
current data, we can say that the most effective regimen is
combined doxycycline for 45 days with streptomycin for 14 days
or gentamycin 7 days. The alternative is combined doxycycline
and rifampicin. Other combinations such as ofloxacin and
rifampicin have similar efficacy as well as fewer side effects.
However they are more expensive. Combined doxycycline-co-
trimoxazole could also offer a low-cost alternative. We do not feel
that triple therapy with doxycycline-rifampicin-aminoglycoside
can be recommended as the best regimen in view of current data.
Since brucellosis affects mainly developing countries and mobilizes
economic resources in terms of drugs, other medical supplies and
hospital stays, it is even more important to find simple and
inexpensive medical solutions. Among these solutions, monother-
apy with doxycycline should not be dismissed, especially in
patients with a low risk of relapse. For future studies on this issue,
we suggest a more personalized treatment according to patient
characteristics and risk of relapse.
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